Consult Sciences Ltd · suite hub
Know what is moving in pharma.
And what the evidence actually says.
AEaH is the home of two working tools. PharmaTerminal monitors the market, pipeline, clinical trials and approvals as they change. Nebula maps the peer-reviewed literature behind a technology, so a claim can be traced to the papers that support it.
Two questions, two tools
They are deliberately separate products, because they answer different questions and carry different data. Used together they close a diligence loop; used separately each stands on its own.
Monitoring · paid tiers
PharmaTerminal
A live terminal for pharma R&D: what moved today, what is in the pipeline, what regulators are about to act on, and which trials are enrolling.
- Nine-widget dashboard you can rearrange and resize
- Market movers, global pharma indices and a breaking-news feed
- PDUFA / action dates and recent authorisations from openFDA
- Active clinical trials with phase, enrolment and endpoints
- Pipeline tracker with your own watchlist
- Change alerts on watched compounds, delivered to Telegram
- Compound analysis with export to CSV, and PDF on paid tiers
Evidence mapping · free · beta
Nebula
An interactive map of peer-reviewed publication evidence for a technology or indication — literature as a navigable structure rather than a search box.
- 3D citation map rendered in the browser (WebGL, no server round-trip)
- Currently demonstrating a curated MSC-secretome corpus of ~60 papers
- Grouped into eight disease clusters: secretome & EVs, osteoarthritis, cardiac/MI, COVID/lung, neuro/SCI/ocular, liver, kidney, wound/skin
- Force-directed layout, so spatial closeness approximates topical relatedness
- Click a paper for its metadata, abstract summary and DOI link
- Export the corpus and edge list as JSON or a ZIP
- Free, browsable without an account, no analytics
Straight from the feeds
Both panels below are read from PharmaTerminal at request time. They are here as a demonstration that the tools are running on real sources, not as editorial.
Breaking pharma news
| 1d ago | How AI-enabled predictive intelligence is becoming a new advantage in solid tumor drug development NEWS |
| 1d ago | Navigating Major Inflection Points from IND to Approval APPROVAL |
| 1d ago | AI-Powered CMC Authoring: Keep Your Dossier in Sync NEWS |
| 2d ago | Advancing Low-Temperature Performance: Testing, Trends, and Containment for Cell Therapies NEWS |
| 2d ago | Beyond Conventional Neoantigen Discovery: Expanding the Search for Clinically Relevant Targets with AI PIPELINE |
Recent FDA authorisations
| Date | Brand | Sponsor | Type |
|---|---|---|---|
| 2026-09-18 | SOHONOS | IPSEN | NDA |
| 2026-04-13 | FILSPARI | TRAVERE | NDA |
| 2024-06-21 | SIRTURO | JANSSEN THERAP | NDA |
| 2024-05-16 | REBLOZYL | CELGENE CORP | BLA |
| 2023-12-15 | ZORYVE | ARCUTIS | NDA |
| 2021-10-28 | PONVORY | VANDA PHARMS INC | NDA |
| 2021-06-25 | ADHANSIA XR | KNOA PHARMA | NDA |
How they fit together
A diligence question rarely stops at “what is happening?” or “what does the literature say?” — it needs both, in order.
Step 1 · monitor
Notice the movement
PharmaTerminal watches the surface area where activity shows up first: filings, approvals, trial registrations, readouts and price. Add the compounds you care about to a watchlist and let the alert engine tell you when something actually changed.
Step 2 · substantiate
Check it against the evidence
Nebula takes the mechanism behind that movement and lays out the publication record supporting it — clustered by area of application, with each paper linked to its DOI. You can see at a glance whether a story rests on a broad literature or a single paper.
Step 3 · decide
Bring your own conclusion
Neither tool predicts whether a drug will work, and neither tells you what to buy. They shorten the distance between a question and the sources that bear on it. The judgement stays where it belongs: with you.
Start using them
PharmaTerminal has a free tier and paid tiers for heavier monitoring and analysis. Nebula is free while in beta.
Need it done for you?
Consult Sciences Ltd carries out therapeutic and evidence diligence directly, using these tools, for teams without the bandwidth to run them.